Cue Biopharma, Inc. (NASDAQ:CUE – Get Free Report) insider Sumita Ray sold 1,844 shares of the company’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.05, for a total transaction of $51,724.20. Following the sale, the insider directly owned 116,701 shares of the company’s stock, valued at $3,273,463.05. The trade was a 1.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Sumita Ray also recently made the following trade(s):
- On Thursday, August 13th, Sumita Ray sold 8,829 shares of Cue Biopharma stock. The shares were sold at an average price of $30.09, for a total transaction of $265,664.61.
Cue Biopharma Stock Performance
Shares of NASDAQ:CUE traded down $0.97 during midday trading on Wednesday, hitting $18.60. The company’s stock had a trading volume of 244,958 shares, compared to its average volume of 475,854. The business’s 50 day simple moving average is $27.73 and its 200 day simple moving average is $72.25. The company has a market cap of $135.04 million, a P/E ratio of -0.69 and a beta of 2.62. Cue Biopharma, Inc. has a 12-month low of $4.97 and a 12-month high of $45.50.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on CUE shares. B. Riley Financial assumed coverage on Cue Biopharma in a report on Friday, September 18th. They set a “buy” rating and a $83.00 target price on the stock. Wall Street Zen lowered Cue Biopharma from a “sell” rating to a “strong sell” rating in a research report on Saturday, September 26th. Weiss Ratings cut Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, August 27th. Finally, Zacks Research upgraded Cue Biopharma to a “hold” rating in a research report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Cue Biopharma has an average rating of “Hold” and an average price target of $83.00.
Get Our Latest Stock Report on CUE
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. purchased a new position in Cue Biopharma during the second quarter worth about $1,824,000. ADAR1 Capital Management LLC acquired a new position in Cue Biopharma in the 2nd quarter valued at about $1,742,000. Citadel Advisors LLC grew its stake in shares of Cue Biopharma by 301.8% in the 2nd quarter. Citadel Advisors LLC now owns 25,633 shares of the company’s stock valued at $809,000 after buying an additional 38,333 shares during the period. Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Cue Biopharma in the 2nd quarter valued at approximately $722,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Cue Biopharma during the 2nd quarter worth approximately $389,000. Institutional investors and hedge funds own 35.04% of the company’s stock.
About Cue Biopharma
Cue Biopharma, Inc is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s approach is based on its proprietary Immuno-STAT (Selective Targeting of Antigenic T cells) platform, which is designed to selectively activate and expand disease-specific T cells in the body while potentially reducing the broad immune activation associated with some conventional immunotherapies.
Cue Biopharma’s pipeline includes biologic product candidates intended to target cancer-associated antigens.
See Also
- Five stocks we like better than Cue Biopharma
- Tesla Wants to Make Its Own Chips—What Could Go Wrong?
- IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
- PBF Energy’s Stunning Rally Faces a Critical Test
- Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
